Dr. Kin on Triplet Regimens for Relapsed Multiple Myeloma

Andrew Kin, MD
Published: Monday, Sep 17, 2018



Andrew Kin, MD, assistant professor, Karmanos Cancer Institute, discusses triplet regimens for the treatment of patients with relapsed multiple myeloma.

Almost all of the recent clinical trials in the relapsed setting have been looking at 3-drug regimens versus dual combinations, Kin says. These triplet combinations have usually been adding to a backbone of lenalidomide (Revlimid) and dexamethasone or bortezomib (Velcade) and dexamethasone. Across the board, data show an improvement in outcomes for patients treated with a triplet versus a doublet. Kin says it’s pretty clear that if a patient is fit enough and doesn’t have any preexisting toxicity issues, then they should be treated with a 3-drug regimen.

Data with daratumumab (Darzalex), bortezomib, and dexamethasone have also been impressive, Kin adds, in terms of depth and duration of response. There is also the potential to de-escalate daratumumab dosing and utilize it as an essential second maintenance phase.


Andrew Kin, MD, assistant professor, Karmanos Cancer Institute, discusses triplet regimens for the treatment of patients with relapsed multiple myeloma.

Almost all of the recent clinical trials in the relapsed setting have been looking at 3-drug regimens versus dual combinations, Kin says. These triplet combinations have usually been adding to a backbone of lenalidomide (Revlimid) and dexamethasone or bortezomib (Velcade) and dexamethasone. Across the board, data show an improvement in outcomes for patients treated with a triplet versus a doublet. Kin says it’s pretty clear that if a patient is fit enough and doesn’t have any preexisting toxicity issues, then they should be treated with a 3-drug regimen.

Data with daratumumab (Darzalex), bortezomib, and dexamethasone have also been impressive, Kin adds, in terms of depth and duration of response. There is also the potential to de-escalate daratumumab dosing and utilize it as an essential second maintenance phase.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Moving Forward From the Status Quo for the Treatment of Soft Tissue Sarcoma: Key Questions and New Answers to Optimize OutcomesOct 31, 20182.0
Hematology Briefings™: Advancing Care and Improving Outcomes for Patients With Pyruvate Kinase DeficiencyOct 31, 20181.0
Publication Bottom Border
Border Publication
x